New growth hormone injection aims to help short children grow taller

NCT ID NCT07450053

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called GenSci134, a growth hormone injection, in 128 children with idiopathic short stature (short height with no known cause). The trial has two parts: first, a single-dose phase to check safety and how the body processes the drug; second, a multiple-dose phase comparing GenSci134 to an existing growth hormone (Norditropin) to see if it improves growth rate over 24 weeks. The goal is to find the right dose and confirm it is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GenSci134 (a new growth hormone injection)
What this could lead to
If successful, this could offer a new treatment option to help children with idiopathic short stature grow taller.
What could go wrong
This is an early-phase trial with only 128 participants, so results may not apply to all children. The new drug may not work better than existing growth hormone or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC SHORT STATURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

    Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.